- Home
- PYN vs GDTC Comparison
PYN vs GDTC Comparison
Compare PYN & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYN
- GDTC
- Stock Information
- Founded
- PYN 2002
- GDTC 2018
- Country
- PYN United States
- GDTC Singapore
- Employees
- PYN N/A
- GDTC N/A
- Industry
- PYN Investment Managers
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- PYN Finance
- GDTC Health Care
- Exchange
- PYN Nasdaq
- GDTC Nasdaq
- Market Cap
- PYN 30.1M
- GDTC 28.0M
- IPO Year
- PYN N/A
- GDTC 2023
- Fundamental
- Price
- PYN $5.27
- GDTC $2.08
- Analyst Decision
- PYN
- GDTC Buy
- Analyst Count
- PYN 0
- GDTC 1
- Target Price
- PYN N/A
- GDTC $5.00
- AVG Volume (30 Days)
- PYN 19.9K
- GDTC 5.7K
- Earning Date
- PYN 01-01-0001
- GDTC 01-01-0001
- Dividend Yield
- PYN 5.07%
- GDTC N/A
- EPS Growth
- PYN N/A
- GDTC N/A
- EPS
- PYN N/A
- GDTC N/A
- Revenue
- PYN N/A
- GDTC $368,838.00
- Revenue This Year
- PYN N/A
- GDTC $5.37
- Revenue Next Year
- PYN N/A
- GDTC N/A
- P/E Ratio
- PYN N/A
- GDTC N/A
- Revenue Growth
- PYN N/A
- GDTC N/A
- 52 Week Low
- PYN $4.84
- GDTC $1.20
- 52 Week High
- PYN $6.60
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- PYN 48.20
- GDTC 48.83
- Support Level
- PYN $5.20
- GDTC $2.07
- Resistance Level
- PYN $5.30
- GDTC $2.34
- Average True Range (ATR)
- PYN 0.05
- GDTC 0.09
- MACD
- PYN 0.01
- GDTC 0.00
- Stochastic Oscillator
- PYN 70.00
- GDTC 50.97
About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest
PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.